TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:06
ADC Therapeutics SA ( ADCT ) https://www.adctherapeutics.com
1.28USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Switzerland
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-63.64%
ADCT
SPY
30.72%
-96.49%
ADCT
SPY
112.82%
ADCT
0.00%
SPY
201.04%
ADCT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
105.29
-65.84
0.82
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.59
0.86
-1.94
-136.53
0.00
0.49
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-258.08
97.47
-109.77
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-31.62
-34.11
0.00
Other Earnings and Cash Flow Stats:
ADC Therapeutics SA ( ADCT ) Net Income TTM ($MM) is -182.00
ADC Therapeutics SA ( ADCT ) Operating Income TTM ($MM) is -92.85
ADC Therapeutics SA ( ADCT ) Owners' Earnings Annual ($MM) is -139.22
ADC Therapeutics SA ( ADCT ) Current Price to Owners' Earnings ratio is -2.22
ADC Therapeutics SA ( ADCT ) EBITDA TTM ($MM) is -88.08
ADC Therapeutics SA ( ADCT ) EBITDA Margin is -109.77%
Capital Allocation:
ADC Therapeutics SA ( ADCT ) has paid 0.00 dividends per share and bought back -16.846555 million shares in the past 12 months
ADC Therapeutics SA ( ADCT ) has increased its debt by 8.329 million USD in the last 12 months
Capital Structure:
ADC Therapeutics SA ( ADCT ) Interest-bearing Debt ($MM) as of last quarter is 139
ADC Therapeutics SA ( ADCT ) Annual Working Capital Investments ($MM) are 2
ADC Therapeutics SA ( ADCT ) Book Value ($MM) as of last quarter is -55
ADC Therapeutics SA ( ADCT ) Debt/Capital as of last quarter is -258%
Other Balance Sheet Stats:
ADC Therapeutics SA ( ADCT ) has 310 million in cash on hand as of last quarter
ADC Therapeutics SA ( ADCT ) has 78 million of liabilities due within 12 months, and long term debt 112 as of last quarter
ADC Therapeutics SA ( ADCT ) has 82 common shares outstanding as of last quarter
ADC Therapeutics SA ( ADCT ) has 0 million USD of preferred stock value
Academic Scores:
ADC Therapeutics SA ( ADCT ) Altman Z-Score is -3.54 as of last quarter
ADC Therapeutics SA ( ADCT ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
ADC Therapeutics SA ( ADCT ) largest shareholder is Morgan Stanley - Brokerage Accounts owning 664027 shares at 0.85 ($MM) value
(an insider) shares of ADC Therapeutics SA ( ADCT ) for the amount of $ on
32.61% of ADC Therapeutics SA ( ADCT ) is held by insiders, and 62.43% is held by institutions
ADC Therapeutics SA ( ADCT ) went public on 1979-03-16
Other ADC Therapeutics SA ( ADCT ) financial metrics:
FCF:-101.64
Unlevered Free Cash Flow:-139.08
EPS:-2.32
Operating Margin:-258.08
Gross Profit Margin:97.47
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:352.94
Beta:0.00
Buffet's Owners Earnings:-139.22
Price to Owner's Earnings:-2.22
About ADC Therapeutics SA ( ADCT ) :
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.